Literature DB >> 24907868

HIV infection: epidemiology, pathogenesis, treatment, and prevention.

Gary Maartens1, Connie Celum2, Sharon R Lewin3.   

Abstract

HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012. Global AIDS-related deaths peaked at 2.3 million in 2005, and decreased to 1.6 million by 2012. An estimated 9.7 million people in low-income and middle-income countries had started antiretroviral therapy by 2012. New insights into the mechanisms of latent infection and the importance of reservoirs of infection might eventually lead to a cure. The role of immune activation in the pathogenesis of non-AIDS clinical events (major causes of morbidity and mortality in people on antiretroviral therapy) is receiving increased recognition. Breakthroughs in the prevention of HIV important to public health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis. Research into other prevention interventions, notably vaccines and vaginal microbicides, is in progress.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24907868     DOI: 10.1016/S0140-6736(14)60164-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  250 in total

1.  Communicable and non-communicable diseases: connections, synergies and benefits of integrating care.

Authors:  A D Harries; A M V Kumar; S Satyanarayana; Y Lin; K C Takarinda; H Tweya; A J Reid; R Zachariah
Journal:  Public Health Action       Date:  2015-09-21

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 3.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

4.  The immunosuppressive domain of the transmembrane envelope protein gp41 of HIV-1 binds to human monocytes and B cells.

Authors:  Michael Mühle; Tobias Kroniger; Kerstin Hoffmann; Joachim Denner
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 5.  Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Authors:  Daniela F Passos; Maria Rosa C Schetinger; Daniela Br Leal
Journal:  World J Virol       Date:  2015-08-12

6.  Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study.

Authors:  Sebastiano Leone; Milensu Shanyinde; Alessandro Cozzi Lepri; Fiona C Lampe; Pietro Caramello; Andrea Costantini; Andrea Giacometti; Andrea De Luca; Antonella Cingolani; Francesca Ceccherini Silberstein; Massimo Puoti; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-09       Impact factor: 3.267

7.  Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.

Authors:  Sebastiano Leone; Patrizia Lorenzini; Alessandro Cozzi-Lepri; Giancarlo Orofino; Dario Bernacchia; Antonella Castagna; Marianna Menozzi; Giovanni Guaraldi; Giordano Madeddu; Antonio Di Biagio; Massimo Puoti; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-22       Impact factor: 3.267

8.  A 10 years audit of cardiothoracic referrals from a pulmonology service in a developing country: impact of patient human immunodeficiency virus status.

Authors:  George Mwamnemo Nyale; Ronald Anderson; Atulkumar Ramanlal Patel; Charles Feldman
Journal:  Ann Transl Med       Date:  2016-04

9.  Does cerumen have a risk for transmission of HIV?

Authors:  F M Hanege; M T Kalcioglu; F Sargin; Z Cetinkaya; M Tekin; H Vahaboglu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-06       Impact factor: 3.267

10.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.